Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for Roivant Sciences (ROIV) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Roivant Sciences' Cash & Equivalents fell 36.84% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 36.84%. This contributed to the annual value of $2.7 billion for FY2025, which is 58.19% down from last year.
  • Per Roivant Sciences' latest filing, its Cash & Equivalents stood at $1.2 billion for Q3 2025, which was down 0.12% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Roivant Sciences' Cash & Equivalents registered a high of $6.7 billion during Q4 2023, and its lowest value of $1.2 billion during Q3 2025.
  • For the 3-year period, Roivant Sciences' Cash & Equivalents averaged around $3.0 billion, with its median value being $2.0 billion (2024).
  • As far as peak fluctuations go, Roivant Sciences' Cash & Equivalents surged by 338.64% in 2023, and later slumped by 78.27% in 2025.
  • Over the past 5 years, Roivant Sciences' Cash & Equivalents (Quarterly) stood at $2.2 billion in 2021, then tumbled by 31.02% to $1.5 billion in 2022, then spiked by 338.64% to $6.7 billion in 2023, then slumped by 70.29% to $2.0 billion in 2024, then tumbled by 36.84% to $1.2 billion in 2025.
  • Its Cash & Equivalents was $1.2 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $2.7 billion in Q1 2025.